Placebo-Controlled Does Not Mean Good Science
A personal essay, not an evidence assessment. Our graded assessments of individual ingredients — written to a published standard, from full texts — are in the evidence section. Nothing here is a statement about what any product does.
There is something reassuring about the phrase:
double-blind, placebo-controlled trial.
It sounds like scientific armour.
Once those words appear, people often stop asking questions.
I do not.
A placebo control is valuable.
Blinding is valuable.
Randomisation is valuable.
But none of them individually guarantees that the study produced a trustworthy answer.
Was the placebo believable?
This is particularly important in supplementation research.
Suppose the active product:
tastes bitter, causes tingling, increases alertness, changes heart rate, or produces a distinctive sensation.
And placebo tastes like flavoured water.
Participants may quickly work out which group they are in.
Researchers may notice too.
At that point the trial can remain technically labelled “blinded” while the practical blinding has weakened.
Modern reporting standards explicitly emphasise how blinding was achieved, because discernible differences such as colour or taste can create bias problems.
Was allocation concealed?
This happens before blinding even becomes relevant.
The people recruiting participants should not be able to predict which intervention comes next.
Allocation-sequence concealment is distinct from blinding because it protects against biased assignment before or at enrolment.
A study can call itself randomised and still handle the randomisation process poorly.
What was the comparator supposed to answer?
Placebo is not always the scientifically important comparator.
For:
A + caffeine versus placebo the study can test whether the combination differs from no active intervention.
But if I want to know:
Does A add something to caffeine?
I need:
A + caffeine versus caffeine.
“Placebo-controlled” sounds rigorous.
The wrong comparator can still leave the central question unanswered.
What happened to the participants?
How many dropped out?
Why?
Were dropouts similar between groups?
Did participants remain in the analysis?
Missing data can distort otherwise elegant experiments.
Modern risk-of-bias frameworks evaluate specific results because different outcomes or time points within the same RCT may carry different risks - for example because attrition increases at later follow-up.
This is a useful reminder:
there is no magical property called “good RCT.”
We have to examine the result we want to use.
What was chosen after the data were visible?
A protocol might define one primary outcome.
The final paper may emphasise another.
A subgroup may become suddenly fascinating.
An unexpected secondary endpoint may migrate into the abstract.
Again, none of this automatically means misconduct.
But interpretation changes.
Placebo-controlled is a design feature
Not a certificate.
When I see it, I am encouraged.
Then I continue reading.
Because the right question is never:
Was there a placebo?
It is:
Did the entire design make it difficult for bias, chance and expectation to manufacture the observed result?
That is a much higher standard.
And it should be.
Methodological sources
Reporting and appraisal standards referred to in this essay. They are not the evidence behind any product claim.